Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.45+0.02 (+4.90%)
Close on Nov 18, 2026Market cap $6.88MP/E –Yield –
Dare Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Dare Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$11.11M. For fiscal 2025 it was -$13.55M. The highest annual figure on record is -$630.59K in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.55M | – |
| FY2024 | Dec 31, 2024 | -$23.45M | – |
| FY2023 | Dec 31, 2023 | -$30.94M | – |
| FY2022 | Dec 31, 2022 | -$31.39M | – |
| FY2021 | Dec 31, 2021 | -$39.07M | – |
| FY2020 | Dec 31, 2020 | -$27.40M | – |
| FY2019 | Dec 31, 2019 | -$14.34M | – |
| FY2018 | Dec 31, 2018 | -$16.88M | – |
| FY2017 | Dec 31, 2017 | -$11.18M | – |
| FY2016 | Dec 31, 2016 | -$630.59K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.99M | -2439.0% |
| Q1 FY2023 | Mar 31, 2023 | -$8.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.14M | – |
| Q2 FY2022 | Jun 30, 2022 | $384.32K | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.69M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.58M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.96M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.62M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.68M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.14M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.33M | – |
| Q2 FY2017 | Jun 30, 2017 | -$479.62K | – |
| Q1 FY2017 | Mar 31, 2017 | -$228.46K | – |
| Q4 FY2016 | Dec 31, 2016 | -$188.64K | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.96K | – |
See a number that looks wrong?